Mattias Rudebeck, PhD MSc BMedSc
Immedica Pharma AB
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mattias Rudebeck, PhD MSc BMedSc as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:54 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06582524 · Pegzilarginase in Subjects <24 Months Old With Arginase 1 DeficiencyImmedica Pharma AB · completed · Arginase 1 Deficiency · study director
- Ph3NCT03921541 · Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 DeficiencyImmedica Pharma AB · completed · Arginase I Deficiency, Hyperargininemia · study director
- Ph2NCT03378531 · A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 DeficiencyImmedica Pharma AB · completed · Arginase I Deficiency, Hyperargininemia · study director
- Ph1/Ph2NCT03371979 · Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung CancerImmedica Pharma AB · terminated · Small-cell Lung Cancer · study director
- Ph1NCT02732184 · A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDSImmedica Pharma AB · completed · Acute Myeloid Leukemia, Myelodysplastic Syndrome · study director
- Ph1NCT02561234 · A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid TumorsImmedica Pharma AB · completed · Advanced Cancers · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.